FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885710087> ?p ?o ?g. }

• W2885710087 abstract "Background: Drug resistance remains a significant limitation to the clinical use of 5-Fluorouracil (5-FU) in lung cancer. With cancer cell metabolism emerging as a critical regulator of tumor progression, combining 5-FU with an inhibitor of the metabolic machinery represents a potential therapeutic strategy to prevent lung cancer progression. Cancer cell metabolism is reprogrammed wherein glutamine utilization is increased via elevation of glutaminase activity thereby generating the necessary substrates required for eventual ATP synthesis and energy production. RP10107 is a novel, potent, and selective glutaminase (GLS-1) inhibitor that demonstrated high potency against mouse (IC 50 =21.2 nM), rat (IC 50 =18.2 nM) and human (IC 50 =26.4 nM) enzymes with selectivity over GLS-2 (>380-fold). The objective of this study was to evaluate the effect of a combination of 5-FU and RP10107 in lung cancer cells. Methods: Glutamate concentrations in lung cancer cell lines (A549, NCI-H460, NCI-H1975, NCI-H441, and NCI-H2170) following treatment with RP10107 was estimated by LC-MS/MS. Synergism with 5-FU was determined using different concentrations of the compounds in a 5 x 5 grid. Synergism, additivity, or antagonism was calculated based on the BLISS score. Apoptosis was determined by Annexin V/7AAD staining using a MUSE® Annexin V and dead cell assay kit (Millipore) while the effect on cell cycle was estimated using Guava Cell Cycle Reagent (Millipore). Expression of caspase 3/7, phosphor-p53 (S15), and Bcl-2 were determined by Western Blotting. Results: Treatment of lung cancer cell lines with RP10107 resulted in an increased ratio of glutamine to glutamate with a doubling noticed between 100-300 nM. The change in glutamine utilization was accompanied by a dose-dependent inhibition in cell growth with half-maximal inhibitions ranging from 1.3 to 9.0 μM. Synergism or additivity between RP10107 and 5-FU for anti-proliferative activity was noticed in all the cell lines tested with effect being most pronounced in NCI-H460 and NCI-H441. Additionally, incubation with the combination (1-5 μM RP10107 + 3-5 μM 5-FU) for 48-72 h caused a G2/M or S-phase arrest with a corresponding increase in the percent of apoptotic cells (1-5 to 2.5-fold) compared to the individual agents. Combination of RP10107 and 5-FU increased expression of phospho-p53 expression in all cell lines tested while it led to 40-75% reduction in caspase 3, caspase 7, and Bcl-2 in NCI-H2170 and NCI-H460. Conclusions: Addition of RP10107, a potent glutaminase inhibitor, potentiated 5-FU activity in lung cancer cell lines. Findings provide a rationale for use of the combination in future clinical trials involving lung cancer patients thereby providing a safer and more effective alternative to currently available therapy. Citation Format: Srikant Viswanadha, Satyanarayana Eleswarapu, Seeta Nyayapathy, Swaroop Vakkalanka. Addition of RP10107, a novel and potent glutaminase inhibitor, accentuates 5-FU activity in lung cancer cell lines in vitro [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4875." @default.
• W2885710087 created "2018-08-22" @default.
• W2885710087 creator A5011418059 @default.
• W2885710087 creator A5063852441 @default.
• W2885710087 creator A5071115612 @default.
• W2885710087 creator A5082255146 @default.
• W2885710087 date "2018-07-01" @default.
• W2885710087 modified "2023-09-25" @default.
• W2885710087 title "Abstract 4875: Addition of RP10107, a novel and potent glutaminase inhibitor, accentuates 5-FU activity in lung cancer cell lines in vitro" @default.
• W2885710087 doi "https://doi.org/10.1158/1538-7445.am2018-4875" @default.
• W2885710087 hasPublicationYear "2018" @default.
• W2885710087 type Work @default.
• W2885710087 sameAs 2885710087 @default.
• W2885710087 citedByCount "0" @default.
• W2885710087 crossrefType "proceedings-article" @default.
• W2885710087 hasAuthorship W2885710087A5011418059 @default.
• W2885710087 hasAuthorship W2885710087A5063852441 @default.
• W2885710087 hasAuthorship W2885710087A5071115612 @default.
• W2885710087 hasAuthorship W2885710087A5082255146 @default.
• W2885710087 hasConcept C109549099 @default.
• W2885710087 hasConcept C121608353 @default.
• W2885710087 hasConcept C126322002 @default.
• W2885710087 hasConcept C185592680 @default.
• W2885710087 hasConcept C190283241 @default.
• W2885710087 hasConcept C2775934118 @default.
• W2885710087 hasConcept C2776256026 @default.
• W2885710087 hasConcept C2779349466 @default.
• W2885710087 hasConcept C29537977 @default.
• W2885710087 hasConcept C31573885 @default.
• W2885710087 hasConcept C502942594 @default.
• W2885710087 hasConcept C515207424 @default.
• W2885710087 hasConcept C54355233 @default.
• W2885710087 hasConcept C55493867 @default.
• W2885710087 hasConcept C62112901 @default.
• W2885710087 hasConcept C71924100 @default.
• W2885710087 hasConcept C86803240 @default.
• W2885710087 hasConcept C96232424 @default.
• W2885710087 hasConcept C98274493 @default.
• W2885710087 hasConceptScore W2885710087C109549099 @default.
• W2885710087 hasConceptScore W2885710087C121608353 @default.
• W2885710087 hasConceptScore W2885710087C126322002 @default.
• W2885710087 hasConceptScore W2885710087C185592680 @default.
• W2885710087 hasConceptScore W2885710087C190283241 @default.
• W2885710087 hasConceptScore W2885710087C2775934118 @default.
• W2885710087 hasConceptScore W2885710087C2776256026 @default.
• W2885710087 hasConceptScore W2885710087C2779349466 @default.
• W2885710087 hasConceptScore W2885710087C29537977 @default.
• W2885710087 hasConceptScore W2885710087C31573885 @default.
• W2885710087 hasConceptScore W2885710087C502942594 @default.
• W2885710087 hasConceptScore W2885710087C515207424 @default.
• W2885710087 hasConceptScore W2885710087C54355233 @default.
• W2885710087 hasConceptScore W2885710087C55493867 @default.
• W2885710087 hasConceptScore W2885710087C62112901 @default.
• W2885710087 hasConceptScore W2885710087C71924100 @default.
• W2885710087 hasConceptScore W2885710087C86803240 @default.
• W2885710087 hasConceptScore W2885710087C96232424 @default.
• W2885710087 hasConceptScore W2885710087C98274493 @default.
• W2885710087 hasLocation W28857100871 @default.
• W2885710087 hasOpenAccess W2885710087 @default.
• W2885710087 hasPrimaryLocation W28857100871 @default.
• W2885710087 hasRelatedWork W2004772109 @default.
• W2885710087 hasRelatedWork W2379596105 @default.
• W2885710087 hasRelatedWork W2380573368 @default.
• W2885710087 hasRelatedWork W2387887448 @default.
• W2885710087 hasRelatedWork W2512505240 @default.
• W2885710087 hasRelatedWork W2620164270 @default.
• W2885710087 hasRelatedWork W2790456193 @default.
• W2885710087 hasRelatedWork W2804936547 @default.
• W2885710087 hasRelatedWork W2938644276 @default.
• W2885710087 hasRelatedWork W3029321351 @default.
• W2885710087 isParatext "false" @default.
• W2885710087 isRetracted "false" @default.
• W2885710087 magId "2885710087" @default.
• W2885710087 workType "article" @default.